BioSpace News Archive

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today it will release its second quarter 2021 financial results after the market closes on Wednesday, August 4, 2021.

Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced the online publication of new analysis evaluating the efficacy and safety of ZYNRELEF

MorphoSys AG, a commercial-stage biopharmaceutical company and a leader in antibody and protein technologies, will publish its results for the second quarter and first half 2021 on July 28, 2021 at 10:00pm CEST.

Kane Biotech Inc., announces that it has cancelled 8,470,555 stock options of the Company of various directors, officers, employees and consultants of the Company.

ICON plc, a world-leading healthcare intelligence and clinical research organisation, reported its financial results for the second quarter ended June 30, 2021.

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2021 on Wednesday, July 28, 2021, after the market closes.

Antiviral combination therapies are pharmaceutical medications manufactured with the formulation of more than two drugs for treating various viral diseases including hepatitis C, hepatitis B, and Human Immune Deficiency (HIV) virus.

Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK), today announced that the Bellberry Human Research Ethics Committee (HREC) in Australia has approved the clinical trial application of the phase 1 trial of ATG-101 in patients with metastatic/advanced solid tumors and B-cell non-Hodgkin’s lymphoma (B-NHL)

Pharmacovigilance has evolved considerably thanks to strict monitoring in place jointly by the pharma consortium and regulatory bodies in several parts of the world.

Genentech, a member of the Roche Group, announced that Venclexta® in combination with azacitidine has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration for the treatment of adult patients with previously untreated intermediate, high- and very high-risk myelodysplastic syndromes based on the revised International Prognostic Scoring System.